This panel discussed recent developments in the economic and legal issues involving the False Claims Act and Anti-Kickback Statute, with a particular focus on the intersection of litigation/investigations and drug pricing.

Panelists

Anupam B. Jena

Ruth L. Newhouse Associate Professor of Health Care Policy, Harvard Medical School; Physician, Department of Medicine, Massachusetts General Hospital

Andrew O’Connor

Partner and Co-Leader, Health Care and Life Sciences Industry Group, Ropes & Gray

Christopher Ody

Vice President, Analysis Group

Jesse Siegel

Assistant General Counsel, Ipsen Biopharmaceuticals

Moderator

Crystal Pike

Managing Principal, Analysis Group

False Claims Act and Drug Pricing-Related Cases